UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction

Current opinion in endocrinology, diabetes, and obesity, 2014-10, Vol.21 (5), p.345-351

Bays, Harold

2014

Volltextzugriff (PDF)

Adiposopathy is "sick fat" a cardiovascular disease?

Journal of the American College of Cardiology, 2011-06, Vol.57 (25), p.2461-2473

Bays, Harold E

2011

Volltextzugriff (PDF)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

Diabetes therapy, 2013-12, Vol.4 (2), p.195-220

Bays, Harold

2013

Volltextzugriff (PDF)

“Sick Fat,” Metabolic Disease, and Atherosclerosis

The American journal of medicine, 2009, Vol.122 (1), p.S26-S37

Bays, Harold E., MD

2009

Volltextzugriff (PDF)

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

The New England journal of medicine, 2019-03, Vol.380 (11), p.1022-1032

2019

Volltextzugriff (PDF)

Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids

The American journal of cardiology, 2006-08, Vol.98 (4), p.71-76

Bays, Harold

2006

Volltextzugriff (PDF)

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.129-169

2015

Volltextzugriff (PDF)

Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

Obesity (Silver Spring, Md.), 2020-05, Vol.28 (5), p.870-881

2020

Volltextzugriff (PDF)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

Obesity (Silver Spring, Md.), 2014-04, Vol.22 (4), p.1042-1049

2014

Volltextzugriff (PDF)

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

Journal of clinical lipidology, 2014-09, Vol.8 (5), p.473-488

2014

Volltextzugriff (PDF)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

European journal of preventive cardiology, 2020-04, Vol.27 (6), p.593-603

2020

Volltextzugriff (PDF)

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Diabetes care, 2017-05, Vol.40 (5), p.632-639

2017

Volltextzugriff (PDF)

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

The American journal of cardiology, 2012-10, Vol.110 (7), p.984-992

2012

Volltextzugriff (PDF)

Safety Considerations with Omega-3 Fatty Acid Therapy

The American journal of cardiology, 2007-03, Vol.99 (6), p.S35-S43

Bays, Harold E., MD

2007

Volltextzugriff (PDF)

Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies

The American journal of cardiology, 2012-11, Vol.110 (9), p.4B-12B

Bays, Harold E., MD

2012

Volltextzugriff (PDF)

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Nature medicine, 2023-07, Vol.29 (7), p.1782-1792

2023

Volltextzugriff (PDF)

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

The American journal of cardiology, 2011-09, Vol.108 (5), p.682-690

2011

Volltextzugriff (PDF)

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

The American journal of cardiology, 2016-12, Vol.118 (12), p.1805-1811

2016

Volltextzugriff (PDF)

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

The American heart journal, 2021-05, Vol.235, p.104-112

2021

Volltextzugriff (PDF)

Current and investigational antiobesity agents and obesity therapeutic treatment targets

Obesity (Silver Spring, Md.), 2004-08, Vol.12 (8), p.1197-1211

Bays, H.E

2004

Volltextzugriff (PDF)

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

The journal of clinical endocrinology and metabolism, 2015-08, Vol.100 (8), p.3140-3148

2015

Volltextzugriff (PDF)

Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity Pillars (Online), 2022-03, Vol.1, p.100004-100004, Article 100004

2022

Volltextzugriff (PDF)

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Journal of the American College of Cardiology, 2013-09, Vol.62 (13), p.1154-1162

2013

Volltextzugriff (PDF)

Safety Considerations with Niacin Therapy

The American journal of cardiology, 2007-03, Vol.99 (6), p.S22-S31

2007

Volltextzugriff (PDF)

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

The New England journal of medicine, 2010-07, Vol.363 (3), p.245-256

2010

Volltextzugriff (PDF)

1 – 25 von 441

Suche als RSS-Feed

Aktive Filter

Publikationsformmagazinearticle

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(400)
Mit Volltextzugriff
(383)

Publikationsform

Sprache

Englisch
(441)
Japanisch
(32)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction

Adiposopathy is "sick fat" a cardiovascular disease?

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

“Sick Fat,” Metabolic Disease, and Atherosclerosis

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Safety Considerations with Omega-3 Fatty Acid Therapy

Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Current and investigational antiobesity agents and obesity therapeutic treatment targets

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Safety Considerations with Niacin Therapy

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

Aktive Filter

Suchergebnisse filtern